These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24310736)

  • 21. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
    Park E; Park J; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Int J Oncol; 2012 Apr; 40(4):1259-66. PubMed ID: 22159814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
    Zheng Y; Yang J; Qian J; Zhang L; Lu Y; Li H; Lin H; Lan Y; Liu Z; He J; Hong S; Thomas S; Shah J; Baladandayuthapani V; Kwak LW; Yi Q
    J Mol Med (Berl); 2012 Jun; 90(6):695-706. PubMed ID: 22207485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.
    Buontempo F; Orsini E; Martins LR; Antunes I; Lonetti A; Chiarini F; Tabellini G; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Cappellini A; Barata JT; Martelli AM
    Leukemia; 2014 Mar; 28(3):543-53. PubMed ID: 24253024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
    Wachsberger PR; Lawrence YR; Liu Y; Rice B; Feo N; Leiby B; Dicker AP
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):573-82. PubMed ID: 24500492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
    Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
    Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
    Gazi M; Moharram SA; Marhäll A; Kazi JU
    Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
    Ren H; Guo H; Thakur A; Zhang S; Wang T; Liang Y; Shi P; Gao L; Liu F; Feng J; Chen T; Yang T; Shang D; Liu JJ; Xu F; Chen M
    Oncotarget; 2016 Oct; 7(41):67277-67287. PubMed ID: 27572309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pan-class I  PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
    Müller A; Gillissen B; Richter A; Richter A; Chumduri C; Daniel PT; Scholz CW
    Cell Death Dis; 2018 Mar; 9(3):384. PubMed ID: 29515122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
    Safaroghli-Azar A; Bashash D; Kazemi A; Pourbagheri-Sigaroodi A; Momeny M
    Eur J Pharmacol; 2019 Jan; 842():89-98. PubMed ID: 30401630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
    Hu Y; Guo R; Wei J; Zhou Y; Ji W; Liu J; Zhi X; Zhang J
    Cell Death Dis; 2015 Dec; 6(12):e2020. PubMed ID: 26673665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of PI3K/AKT signaling using BKM120 reduced the proliferation and migration potentials of colorectal cancer cells and enhanced cisplatin-induced cytotoxicity.
    Khameneh SC; Sari S; Razi S; Yousefi AM; Bashash D
    Mol Biol Rep; 2024 Mar; 51(1):420. PubMed ID: 38483663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.
    Valentino JD; Li J; Zaytseva YY; Mustain WC; Elliott VA; Kim JT; Harris JW; Campbell K; Weiss H; Wang C; Song J; Anthony L; Townsend CM; Evers BM
    Clin Cancer Res; 2014 Mar; 20(5):1212-22. PubMed ID: 24443523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
    Bashash D; Delshad M; Riyahi N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M
    Eur J Pharmacol; 2018 Dec; 841():10-18. PubMed ID: 30316766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
    Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
    Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).
    Matas-Céspedes A; Rodriguez V; Kalko SG; Vidal-Crespo A; Rosich L; Casserras T; Balsas P; Villamor N; Giné E; Campo E; Roué G; López-Guillermo A; Colomer D; Pérez-Galán P
    Clin Cancer Res; 2014 Jul; 20(13):3458-71. PubMed ID: 24799524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
    Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
    Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Andrographolide inhibits growth of human T-cell acute lymphoblastic leukemia Jurkat cells by downregulation of PI3K/AKT and upregulation of p38 MAPK pathways.
    Yang T; Yao S; Zhang X; Guo Y
    Drug Des Devel Ther; 2016; 10():1389-97. PubMed ID: 27114702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma.
    Liu WL; Gao M; Tzen KY; Tsai CL; Hsu FM; Cheng AL; Cheng JC
    Oncotarget; 2014 Jun; 5(11):3662-72. PubMed ID: 25004403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Phosphatidylinositide 3-kinase inhibitor BKM120 suppresses proliferation and promotes apoptosis of U251 glioblastoma cells].
    Qiu Z; Yue S; Chang J; Wang G
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jul; 32(7):936-9. PubMed ID: 27363276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.
    Ren H; Zhao L; Li Y; Yue P; Deng X; Owonikoko TK; Chen M; Khuri FR; Sun SY
    Cancer Lett; 2013 Sep; 338(2):229-38. PubMed ID: 23562472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.